Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

benzinga.com/analyst-stock-ratings/upgrades/25/07/46637016/gileads-newly-approved-hiv-prevention-drug-poised-add-billions-future-sales

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only…

This story appeared on benzinga.com, 2025-07-25 16:12:33.
The Entire Business World on a Single Page. Free to Use →